Filtered By:
Condition: Heart Attack
Drug: Insulin
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 348 results found since Jan 2013.
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
People With Diabetes Are More Vulnerable to Heart Disease. How to Reduce the Risk
If you’ve been diagnosed with diabetes, know that you’ve got plenty of company. The American Diabetes Association (ADA) reports that in 2019, the most recent year for which data is available, 37.3 million adults in the U.S.—about 11.3% of the population—had the chronic condition, and that number continues to grow.
Type 1 diabetes develops when the body isn’t able to produce insulin, and Type 2 occurs when the body doesn’t use insulin correctly. Type 2 is the most common form of diabetes, and when it’s uncontrolled, a person’s blood sugar can jump to dangerous levels that requ...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Elaine K. Howley Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Diabetes mellitus and adverse outcomes after carotid endarterectomy: A systematic review and meta-analysis
CONCLUSIONS: In patients with carotid stenosis treated by CEA, DM is associated with short-term and long-term MAEs. DM may have a greater impact on adverse outcomes in asymptomatic patients after CEA. Insulin-dependent DM may have a more significant impact on post-CEA adverse outcomes than noninsulin-dependent DM. Whether DM management could reduce the risk of adverse outcomes after CEA requires further investigation.PMID:37334731 | DOI:10.1097/CM9.0000000000002730
Source: Chinese Medical Journal - June 19, 2023 Category: General Medicine Authors: Fengshi Li Rui Zhang Xiao Di Shuai Niu Zhihua Rong Changwei Liu Leng Ni Source Type: research
8 Reasons You Get Dizzy
SPECIAL FROM Grandparents.com
Who hasn’t gotten up quickly from sitting down and felt a little bit dizzy? Or had a stomach virus and things spun a bit? But while dizziness can be a side effect of minor health issues, it can also be a sign of a serious health problem.
“Dizziness is absolutely not normal,” says Donnica Moore, M.D., president of Sapphire Women’s Health Group in Chester, N.J. “It tells you that something is wrong. It could be something simple and very easy to fix or it could be a sign of something else going on in your body.”
Dizziness is a more common complaint among older adults—probably bec...
Source: Healthy Living - The Huffington Post - January 4, 2015 Category: Consumer Health News Source Type: news
Proportion of undercarboxylated osteocalcin and serum P1NP predict incidence of myocardial infarction in older men.
CONCLUSIONS: Areduced proportion of undercarboxylated osteocalcin or higherP1NPare associated with increased incidence of MI. UcOC/TOC ratio and P1NP predict risk of MI but not stroke, in a manner distinct from CTX. Further studies are needed to investigate potential mechanisms by which bone turnover markers related to metabolic risk and to collagen formation could modulate cardiovascular risk.
PMID: 26308289 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - August 26, 2015 Category: Endocrinology Authors: Yeap BB, Alfonso H, Chubb SA, Byrnes E, Beilby JP, Ebeling PR, Allan CA, Schultz C, Hankey GJ, Golledge J, Flicker L, Norman PE Tags: J Clin Endocrinol Metab Source Type: research
Diabetes drug may prevent recurring strokes
This study was supported by the NIH's National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Medicine and Health - February 17, 2016 Category: Global & Universal Source Type: news
Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study
ConclusionsRecently diagnosed type 2 diabetes patients showed increased risks of incident CVDs and premature mortality, and insulin ‐treated group demonstrated an additional increase in the risks of these outcomes in adults with recently diagnosed type 2 diabetes, suggesting the need for intensified cardio‐protective interventions for adults with insulin‐treated type 2 diabetes.
Source: Journal of Diabetes Investigation - March 19, 2021 Category: Endocrinology Authors: You ‐Bin Lee,
Kyungdo Han,
Bongsung Kim,
Min Sun Choi,
Jiyun Park,
Minyoung Kim,
Sang‐Man Jin,
Kyu Yeon Hur,
Gyuri Kim,
Jae Hyeon Kim Tags: Original Article Source Type: research
Can DIY and gardening help you live longer?
Conclusion
This study found that in a population-based sample of older adults (aged 60), high levels of non-exercise physical activity, or ‘an active daily life’ was associated with better levels of cardiovascular risk factors.
When followed over time, it was found an active daily life was associated with approximately 30% reduced risk of both a cardiovascular event (stroke, angina, heart attack) and death from any cause.
These associations were seen after adjusting for regular exercise, and for a number of other factors that could explain the association seen (confounders).
This study was a cross-sectional and cohort...
Source: NHS News Feed - October 29, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Heart/lungs Source Type: news
Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: World Pharma News - February 18, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract
During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
CONCLUSIONS
Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.
Source: Diabetes Care - September 21, 2016 Category: Endocrinology Authors: Inzucchi, S. E.; Viscoli, C. M.; Young, L. H.; Furie, K. L.; Gorman, M.; Lovejoy, A. M.; Dagogo-Jack, S.; Ismail-Beigi, F.; Korytkowski, M. T.; Pratley, R. E.; Schwartz, G. G.; Kernan, W. N.; for the IRIS Trial Investigators Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia
In this issue ofJAMA Neurology, Spence et al discuss the effect of pioglitazone, an insulin-sensitizing agent that has been shown to reduce the risk of recurrent stroke and myocardial infarction in patients with insulin resistance, in patients with prediabetes. Prediabetes was defined according to the American Diabetes Association criteria, ie, a hemoglobin A1c level of 5.7% to 6.4% or a fasting plasma glucose level of 100 to 125 mg/dL. Data were taken from the Insulin Resistance Intervention after Stroke (IRIS) study, an international randomized clinical trial performed in patients with previous stroke or transient ischem...
Source: JAMA Neurology - February 7, 2019 Category: Neurology Source Type: research
